Patient characteristics at trial entry
Baseline characteristics . | N (%) (N = 58) . |
---|---|
Age, y | |
Median (range) | 52 (20-68) |
Sex | |
Female | 23 (40%) |
Male | 35 (60%) |
Blood group | |
A | 25 (43%) |
O | 24 (41%) |
B | 6 (10%) |
AB | 3 (5%) |
Ethnicity | |
White | 40 (69%) |
Asian or Asian British | 10 (17%) |
Mixed race | 4 (7%) |
Black or Black British | 3 (5%) |
Chinese | 1 (2%) |
Performance status | |
70% | 2 (3%) |
80% | 5 (9%) |
90% | 27 (47%) |
100% | 24 (41%) |
Primary diagnosis | |
Acute myeloid leukemia | 27 (47%) |
Acute lymphoblastic leukemia | 7 (12%) |
Non-Hodgkin (follicular lymphoma, B-cell lymphoma) | 7 (12%) |
Myelodysplasia syndrome | 7 (12%) |
Other leukemias (chronic myelomonocytic leukemia, T-prolymphocytic leukemia, natural killer cell leukemia) | 3 (5%) |
Hodgkin lymphoma | 3 (5%) |
Acute undifferentiated leukemia | 1 (2%) |
Chronic myeloid leukemia | 1 (2%) |
Multiple myeloma | 1 (2%) |
Primary myelofibrosis transformed to acute myeloid leukemia | 1 (2%) |
Disease status at registration | |
Complete response | 46 (79%) |
Partial response | 8 (14%) |
Progression/relapse | 2 (3%) |
Accelerated phase | 1 (2%) |
Unknown | 1 (2%) |
Comorbidity index | |
0 | 28 (48%) |
1 | 12 (21%) |
2 | 8 (14%) |
3+ | 9 (16%) |
Not reported | 1 (2%) |
Lines of prior treatment | |
0 | 1 (2%) |
1 | 17 (29%) |
2 | 26 (45%) |
3+ | 14 (24%) |
Baseline characteristics . | N (%) (N = 58) . |
---|---|
Age, y | |
Median (range) | 52 (20-68) |
Sex | |
Female | 23 (40%) |
Male | 35 (60%) |
Blood group | |
A | 25 (43%) |
O | 24 (41%) |
B | 6 (10%) |
AB | 3 (5%) |
Ethnicity | |
White | 40 (69%) |
Asian or Asian British | 10 (17%) |
Mixed race | 4 (7%) |
Black or Black British | 3 (5%) |
Chinese | 1 (2%) |
Performance status | |
70% | 2 (3%) |
80% | 5 (9%) |
90% | 27 (47%) |
100% | 24 (41%) |
Primary diagnosis | |
Acute myeloid leukemia | 27 (47%) |
Acute lymphoblastic leukemia | 7 (12%) |
Non-Hodgkin (follicular lymphoma, B-cell lymphoma) | 7 (12%) |
Myelodysplasia syndrome | 7 (12%) |
Other leukemias (chronic myelomonocytic leukemia, T-prolymphocytic leukemia, natural killer cell leukemia) | 3 (5%) |
Hodgkin lymphoma | 3 (5%) |
Acute undifferentiated leukemia | 1 (2%) |
Chronic myeloid leukemia | 1 (2%) |
Multiple myeloma | 1 (2%) |
Primary myelofibrosis transformed to acute myeloid leukemia | 1 (2%) |
Disease status at registration | |
Complete response | 46 (79%) |
Partial response | 8 (14%) |
Progression/relapse | 2 (3%) |
Accelerated phase | 1 (2%) |
Unknown | 1 (2%) |
Comorbidity index | |
0 | 28 (48%) |
1 | 12 (21%) |
2 | 8 (14%) |
3+ | 9 (16%) |
Not reported | 1 (2%) |
Lines of prior treatment | |
0 | 1 (2%) |
1 | 17 (29%) |
2 | 26 (45%) |
3+ | 14 (24%) |